Literature DB >> 23879965

MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).

Meng-Tao Ma1, Miao He, Yan Wang, Xu-Yang Jiao, Lin Zhao, Xue-Feng Bai, Zhao-Jin Yu, Hui-Zhe Wu, Ming-Li Sun, Zhi-Guo Song, Min-Jie Wei.   

Abstract

Breast cancer resistance protein (BCRP/ABCG2) specifically transports various chemotherapeutic agents and is involved in the development of multidrug resistance (MDR) in cancer cells. MicroRNAs (miRNAs) can play an important role in modulating the sensitivity of cancer cells to chemotherapeutic agents. Therefore, after confirming that BCRP was increased in the mitoxantrone (MX)-resistant MCF-7 breast cancer cell line MCF-7/MX compared with its parental sensitive MCF-7 cell line, we aimed to explore the miRNAs that regulate BCRP expression and sensitize breast cancer cells to chemotherapeutic agents. In the present study, bioinformatic analysis indicated that miR-487a was one of the miRNAs that could bind to the 3' untranslated region (3'UTR) of BCRP. Quantitative RT-PCR (qRT-PCR) analysis demonstrated that the expression of miR-487a was reduced in MCF-7/MX cells, and a luciferase reporter assay demonstrated that miR-487a directly bound to the 3'UTR of BCRP. Moreover, ectopic miR-487a down-regulated BCRP expression at the mRNA and protein levels, increasing the intracellular accumulation and cytotoxicity of MX in resistant MCF-7/MX breast cancer cells. Meanwhile, inhibition of miR-487a increased BCRP expression at the mRNA and protein levels and induced MX resistance in sensitive MCF-7 breast cancer cells. Furthermore, the reduced expression of BCRP and increased antitumor effects of MX were also detected in MCF-7/MX xenograft tumors treated with the miR-487a agmir. Thus, our results suggested that miR-487a can directly regulate BCRP expression and reverse chemotherapeutic drug resistance in a subset of breast cancers.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BCRP; Breast cancer; MiR-487a; Multidrug resistance

Mesh:

Substances:

Year:  2013        PMID: 23879965     DOI: 10.1016/j.canlet.2013.07.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  42 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

Review 2.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

Review 3.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

Review 4.  The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs.

Authors:  Y He; J R Chevillet; G Liu; T K Kim; K Wang
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 5.  Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives.

Authors:  Ravi Kasiappan; Dheeran Rajarajan
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

Review 6.  Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation.

Authors:  Juliana Carvalho Santos; Marcelo Lima Ribeiro; Luis Otávio Sarian; Manoela Marques Ortega; Sophie Françoise Derchain
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 7.  Noncoding RNAs in breast cancer.

Authors:  Pang-Kuo Lo; Benjamin Wolfson; Xipeng Zhou; Nadire Duru; Ramkishore Gernapudi; Qun Zhou
Journal:  Brief Funct Genomics       Date:  2015-12-18       Impact factor: 4.241

8.  Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.

Authors:  Ting Chen; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Pengyuan Sun; Jinyong Peng; Zhihao Liu; Xiaobo Yang; Kexin Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 9.  Emerging ways to treat breast cancer: will promises be met?

Authors:  Pouria Samadi; Sahar Saki; Fatemeh Karimi Dermani; Mona Pourjafar; Massoud Saidijam
Journal:  Cell Oncol (Dordr)       Date:  2018-09-27       Impact factor: 6.730

10.  MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway.

Authors:  Qian Jiang; Miao He; Shu Guan; Mengtao Ma; Huizhe Wu; Zhaojin Yu; Longyang Jiang; Yan Wang; Xingyue Zong; Feng Jin; Minjie Wei
Journal:  Tumour Biol       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.